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The requirement to base one’s practice on evidence 
is growing rapidly worldwide. This requirement 
makes sense if you look quite soberly at the issue. 
Who would not want his or her treatment to be 
based on the best possible evidence regarding safety 
and efficacy? Unfortunately, there is a relative lack 
of good safety and efficacy data in the field of child 
and adolescent psychiatry.  
There is longstanding agreement that a 
randomized controlled trial (RCT) is the best 
research design when it comes to examining the 
efficacy of a specific treatment. Systematic reviews, 
which consider data from multiple RCTs, are at the 
top of the evidence hierarchy. However, we lack a 
focus on assessing the quality of RCTs and 
systematic reviews, because there are many 
parameters that can downgrade the quality of these 
methods. In some cases, this means that the 
evidence is very uncertain, even when it is based on 
RCTs and systematic reviews.  
Evidence-based practice is a thorough, explicit, 
rational, and thoughtful use of the best evidence 
available when making decisions related to the 
assessment and treatment of an individual patient. 
In this context, it is essential to integrate individual 
clinical expertise and the patient’s preferences—as 
well as the patient’s parent’s or guardian’s 
preferences, if appropriate—with the best available 
external evidence (1).  
In many medical specialties, medical practitioners 
have used the approach of evidence-based 
treatment for a long time. However, in the field of 
child and adolescent psychiatry, there is still a long 
way to go.  
The childhood cancer specialties have been based 
on evidence for many years. For example, for the 
treatment of children with leukemia, there are now 
clear, step-by-step protocols that are followed. 
Evidence from RCTs has helped oncologists to 
learn more about which treatments are best, and 
evidence from high-quality trials has improved 
cancer survival rates: the annual reduction from 
1978 to 2005 in the risk of death from childhood 
cancer ranged from 2.7% to 12% (2).  
When one looks at the Cochrane Systematic 
Reviews published in the field of child and 
adolescent psychiatry, there is a lack of reviews and 
RCTs of good quality and therefore a lack of 
evidence. There is one new review from 2015 that 
investigated cognitive behavioral therapy for anxiety 
disorders in children and adolescents (3). This 
review included 41 studies and suggested that 
cognitive behavioral therapy is an effective 
treatment for child and adolescent anxiety disorders 
as compared with wait-list controls; however, the 
evidence that suggests that cognitive behavioral 
therapy is more effective than active control 
interventions, treatment as usual, or medication is 
limited and inconclusive. Another review published 
in 2009 investigated the efficacy of pharmaco-
therapy for anxiety disorders in children and 
adolescents and suggested that medications improve 
core symptoms (4). However, all of the trials had a 
high risk of systematic errors, which contributes 
uncertainty to the meta-analytic estimates. When 
one looks at the Cochrane Systematic Reviews that 
have investigated the efficacy of treatment for 
attention-deficit/ hyperactivity disorder, the picture 
is the same: there is a lack of high-quality RCTs, 
which makes the evaluation of treatment efficacy 
uncertain (5-7). Another review that investigated the 
efficacy of antidepressant and psychological 
treatments alone and in combination for depression 
in children and adolescents concluded that there is 
very limited evidence upon which to base 
conclusions about the relative efficacy of 
psychological interventions, antidepressant medica-
tions, or a combination of these (8). A Cochrane 
Systematic Review that investigated the benefits of 
antipsychotic medication for childhood-onset 
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schizophrenia concluded that there was little 
conclusive evidence regarding the effects of 
antipsychotic medication for those individuals with 
early-onset schizophrenia (9). 
This leaves the clinicians who work in the field of 
child and adolescent psychiatry with a poor 
foundation for evidence-based therapy, and they are 
often forced to rely solely upon their clinical 
experience. Why are there fewer high-quality 
treatment studies in this field than in the in the field 
of childhood cancer? One reason may be that, 
unlike most other medical disorders, psychiatric 
disorders may not be considered “real diseases” in 
the minds of many people; this may contribute to 
the poor availability of research funding for child 
and adolescent mental health problems. The Danish 
Council for Independent Research has recently 
given 153.8 million DKK to fund projects in the 
field of health and illness, but none of this money 
was given to projects in the area of Child and 
Adolescent Psychiatry. This is a serious problem, 
because the mortality rate among individuals with 
certain mental illnesses (e.g., depression) is higher 
than that of the general population, and the burden 
of such diseases in the long run is higher than the 
disease burden of many cancers (10). Still, there is a 
lack of evidence for effective treatments, and there 
are also problems with getting children with 
depression into clinics that can provide appropriate 
assessment and diagnosis. There is wide regional 
variation with regard to the availability of mental 
health assessment, and treatment is often based on 
the local standard of practice without the 
consideration of external evidence (2). In addition, 
the adverse effects of treatment are sometimes not 
adequately assessed in the existing treatment studies, 
which is another huge problem (11).  
The extent of actual external evidence in the field 
of child and adolescent psychiatry can practically be 
read as “No evidence for anything.” It is important 
to remember that the absence of evidence is not 
evidence of the absence of effect. The lack of 
external evidence underlines first the need for more 
high-quality research in the area. Increased research 
funding for the field of child and adolescent 
psychiatry is of crucial importance, and this is the 
take-home message for health care policy makers. 
This does not mean that the interventions that are 
currently used in this field are worthless or that they 
should not be used by clinicians. Rather, it means 
that there is a lack of external evidence to support 
the available treatments. It is always the patient who 
is the main focus of evidence-based treatment, as 
stated by the late David Sackett, who was one of the 
founders of evidence-based practice (1). He 
emphasized that the experiences of clinicians should 
be looked at as internal evidence and that this type 
of evidence is equally as important as external 
evidence. He stated that “the practice of evidence-
based medicine means integrating individual clinical 
expertise with the best available external clinical 
evidence from systematic research.” When Sackett 
used the term individual clinical expertise, he was 
referring to the proficiency and judgment that 
individuals acquire through clinical experience and 
clinical practice (12). This means that clinicians 
must continue to use their “best practice” 
approaches, because there is also no evidence that 
these approaches do not represent good treatment. 
It is important to understand this assertion. At the 
same time, it must also be understood that there 
really is a pressing need for additional high-quality 
intervention studies in the field of child and 
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